• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

作者信息

Ray Arghya, Song Yan, Chauhan Dharminder, Anderson Kenneth C

机构信息

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

出版信息

Blood Cancer J. 2019 Aug 12;9(8):64. doi: 10.1038/s41408-019-0224-6.

DOI:10.1038/s41408-019-0224-6
PMID:31406111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6690908/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e647/6690908/f8947b8a3ae2/41408_2019_224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e647/6690908/e94f15e68057/41408_2019_224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e647/6690908/f8947b8a3ae2/41408_2019_224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e647/6690908/e94f15e68057/41408_2019_224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e647/6690908/f8947b8a3ae2/41408_2019_224_Fig2_HTML.jpg

相似文献

1
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.浆细胞样树突状细胞中泛素受体Rpn13的阻断引发抗骨髓瘤免疫。
Blood Cancer J. 2019 Aug 12;9(8):64. doi: 10.1038/s41408-019-0224-6.
2
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.开发并临床前验证了一种新型的骨髓瘤共价泛素受体 Rpn13 降解剂。
Leukemia. 2019 Nov;33(11):2685-2694. doi: 10.1038/s41375-019-0467-z. Epub 2019 Apr 8.
3
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.靶向多发性骨髓瘤中的蛋白酶体泛素受体Rpn13
Leukemia. 2016 Sep;30(9):1877-86. doi: 10.1038/leu.2016.97. Epub 2016 Apr 27.
4
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.候选小分子 RPN13 抑制剂抗肿瘤特性的结构-功能分析。
PLoS One. 2020 Jan 15;15(1):e0227727. doi: 10.1371/journal.pone.0227727. eCollection 2020.
5
Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.RA190 假定的 Rpn13 抑制剂的物理和功能分析。
Cell Chem Biol. 2020 Nov 19;27(11):1371-1382.e6. doi: 10.1016/j.chembiol.2020.08.007. Epub 2020 Aug 27.
6
Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.靶向浆细胞样树突状细胞中的泛素特异性蛋白酶-7可触发抗骨髓瘤免疫。
Leukemia. 2021 Aug;35(8):2435-2438. doi: 10.1038/s41375-021-01129-0. Epub 2021 Jan 24.
7
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.蛋白酶体去泛素化酶抑制剂VLX1570对泛素特异性蛋白酶-14具有选择性，并诱导多发性骨髓瘤细胞凋亡。
Sci Rep. 2016 Jun 6;6:26979. doi: 10.1038/srep26979.
8
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.通过泛素受体ADRM1/Rpn13的蛋白质组学特征鉴定新型抗肿瘤治疗靶点。
Blood Cancer J. 2021 Jan 13;11(1):13. doi: 10.1038/s41408-020-00398-9.
9
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.蛋白质组学分析确定了通过靶向泛素受体 Rpn13 克服硼替佐米耐药的机制。
Leukemia. 2021 Feb;35(2):550-561. doi: 10.1038/s41375-020-0865-2. Epub 2020 May 18.
10
Anti-inflammatory mediators ST2 and SIGIRR are induced by diphenyldifluoroketone EF24 in lipopolysaccharide-stimulated dendritic cells.抗炎介质ST2和SIGIRR由二苯基二氟甲酮EF24在脂多糖刺激的树突状细胞中诱导产生。
Immunobiology. 2020 Mar;225(2):151886. doi: 10.1016/j.imbio.2019.11.021. Epub 2019 Nov 29.

引用本文的文献

1
Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells.咪喹莫特激活的浆细胞样树突状细胞杀瘤能力的多组学及功能表征
iScience. 2025 May 14;28(6):112670. doi: 10.1016/j.isci.2025.112670. eCollection 2025 Jun 20.
2
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.克服蛋白酶体抑制剂耐药性的不同策略——引入 20 年后的总结。
Int J Mol Sci. 2024 Aug 16;25(16):8949. doi: 10.3390/ijms25168949.
3
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.

本文引用的文献

1
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.新型组蛋白去乙酰化酶6（HDAC6）抑制剂ACY-241与抗程序性死亡配体1（PD-L1）抗体联合使用可增强多发性骨髓瘤的抗肿瘤免疫力和细胞毒性。
Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.
2
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.新型药物SL-401通过靶向浆细胞样树突状细胞、破骨细胞生成和癌症干细胞样细胞诱导抗骨髓瘤活性。
Leukemia. 2017 Dec;31(12):2652-2660. doi: 10.1038/leu.2017.135. Epub 2017 May 8.
3
Up284 的开发及抗癌特性：一种新型的候选 ADAM13/RPN13 抑制剂。
PLoS One. 2023 Jun 14;18(6):e0285221. doi: 10.1371/journal.pone.0285221. eCollection 2023.
4
Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy.浆细胞样树突状细胞作为一种新型的基于细胞的癌症免疫疗法。
Int J Mol Sci. 2022 Sep 27;23(19):11397. doi: 10.3390/ijms231911397.
5
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.鉴定和验证外核苷酸酶为多发性骨髓瘤的免疫治疗靶点。
Blood Cancer J. 2022 Apr 1;12(4):50. doi: 10.1038/s41408-022-00635-3.
6
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.2020年/2021年及以后的复发/难治性多发性骨髓瘤
Cancers (Basel). 2021 Oct 14;13(20):5154. doi: 10.3390/cancers13205154.
7
26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.26S 蛋白酶体非-ATP 酶调节亚基 1（PSMD1）和 3（PSMD3）作为癌症预后和治疗的潜在靶点。
Cells. 2021 Sep 11;10(9):2390. doi: 10.3390/cells10092390.
8
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.手性和不对称性增加候选 ADRM1/RPN13 抑制剂的效力。
PLoS One. 2021 Sep 10;16(9):e0256937. doi: 10.1371/journal.pone.0256937. eCollection 2021.
9
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.实验室小鼠——人类多发性骨髓瘤免疫病理学和免疫治疗研究的推动力量。
Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021.
10
Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.靶向活性氧代谢以诱导骨髓瘤细胞死亡。
Cancers (Basel). 2021 May 17;13(10):2411. doi: 10.3390/cancers13102411.
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
19S蛋白酶体亚基的抑制标志着多种癌症中一种改变的细胞状态的出现。
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):382-387. doi: 10.1073/pnas.1619067114. Epub 2016 Dec 27.
4
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.靶向多发性骨髓瘤中的蛋白酶体泛素受体Rpn13
Leukemia. 2016 Sep;30(9):1877-86. doi: 10.1038/leu.2016.97. Epub 2016 Apr 27.
5
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
6
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.蛋白酶体介导的Nrf1加工对于所有蛋白酶体亚基和p97的协同诱导至关重要。
Curr Biol. 2014 Jul 21;24(14):1573-1583. doi: 10.1016/j.cub.2014.06.004. Epub 2014 Jul 3.
7
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.一种新型 TLR-9 激动剂 C792 抑制浆细胞样树突状细胞诱导的骨髓瘤细胞生长并增强硼替佐米的细胞毒性。
Leukemia. 2014 Aug;28(8):1716-24. doi: 10.1038/leu.2014.46. Epub 2014 Jan 30.
8
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.一种针对蛋白酶体泛素受体 RPN13/ADRM1 的双苄叉哌啶酮，可作为癌症的治疗方法。
Cancer Cell. 2013 Dec 9;24(6):791-805. doi: 10.1016/j.ccr.2013.11.001.
9
Therapeutic advances in relapsed or refractory multiple myeloma.复发或难治性多发性骨髓瘤的治疗进展。
J Natl Compr Canc Netw. 2013 May;11(5 Suppl):676-9. doi: 10.6004/jnccn.2013.0199.
10
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.蛋白酶体β5 亚基突变导致硼替佐米结合能力受损是白血病细胞硼替佐米耐药的基础。
Leukemia. 2012 Apr;26(4):757-68. doi: 10.1038/leu.2011.256. Epub 2011 Sep 23.